Heghine Khachatryan: What EHA 2026 Reveals About the Future of Aplastic Anemia Treatment
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared American Society of Hematology’s post on LinkedIn:
“Aplastic Anemia in 2026: Moving Beyond Traditional IST
The management of severe aplastic anemia continues to evolve.
While horse ATG plus cyclosporine remains the backbone of frontline immunosuppressive therapy, recent studies and EHA 2026 discussions highlight the growing role of thrombopoietin receptor agonists (especially eltrombopag) in improving hematologic responses and reducing transfusion dependence.
Key trends shaping 2026 practice include:
- Earlier integration of TPO-receptor agonists into frontline therapy
- Improved risk stratification through molecular profiling and clonal evolution monitoring
- More individualized treatment selection based on age, donor availability, and genomic findings
- Ongoing refinement of the balance between immunosuppression and stem cell transplantation strategies
The future of aplastic anemia treatment is increasingly focused on precision medicine, deeper responses, and long-term prevention of clonal progression.”
American Society of Hematology shared a post on LinkedIn:
“How is frontline immunosuppressive therapy for aplastic anemia evolving in 2026?
Join the next Aplastic Anemia Clinical Case Webinar focusing on highlights from EHA 2026 and practical, evidence-based strategies for patient management.
June 18 | 6–7 p.m.
Register now.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH
-
Sep 25, 2026, 05:24Isabelle Mahé: Reduced-Dose Apixaban in Extended CAT Treatment
-
Sep 25, 2026, 05:15Maria Cherska: High Cholesterol Isn’t Always Diet or Lifestyle – Sometimes It’s Genetic
-
Sep 25, 2026, 05:07Nancy Braithwaite: BBTS Specialist Certificate in Transfusion Science Practice
-
Sep 24, 2026, 18:43Hugh Nguyen: Honored to Accept the Friend of Singapore Red Cross Award
-
Sep 24, 2026, 18:42Titilope Fasipe: Proud to Support American Society of Hematology’s SCD Initiative